C03416: HIF-1aDP, A Constitutively-Expressed form of Hypoxia-Inducible Factor 1a
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
cardiovascular / ischemia (HIF-1alpha stabilization)
Modality
Gene Therapy
Mechanism
HIF-1alpha constitutive expression construct
Target
HIF-1alpha
rNPV Envelope
Low
-$61.3M
costs +25% · peak −25%
Base
-$48.9M
cumulative PoS 0.3%
High
-$36.6M
costs −25% · peak +25%
This is an illustrative, explicitly-hypothetical envelope for cohort consistency only — the asset is a research construct, not a development candidate, and the rNPV is not the decision criterion. Stage costs follow gene-therapy archetype medians (Section 4) for an intramuscular adenoviral angiogenic construct. PoS values are deliberately and heavily depressed at Phase 2/3 because the mechanism-true clinical descendant (Ad2/HIF-1α/VP16) failed a 289-patient randomized Phase II (WALK, Creager 2011) and the entire therapeutic-angiogenesis class — VEGF, FGF (TAMARIS Phase III), HGF (AGILITY Phase III), HIF-1α/VP16 — has no approved product despite a dozen agents tested; cumulative LoA ≈ 0.0033 reflects a clinically de-risked, near-zero-success mechanism.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.70
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.652 — composite-score rank #14 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#46) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Ad2/HIF-1α/VP16 (Genzyme) — adenoviral constitutively-active HIF-1α transgene, WALK trial
Closest mechanism-true clinical translation of this exact concept: an engineered constitutively-active HIF-1α (bHLH-PAS DNA-binding/dimerization domain fused to the HSV VP16 transactivator, removing the oxygen-degradation domain — the same 'truncate away the ODD to make HIF-1α constitutive' strategy this JHU construct embodies). WALK (NCT00117650, Creager 2011 Circulation) randomized 289 intermittent-claudication patients across 3 doses vs placebo; primary endpoint (change in peak walking time at 6 months) was negative and the program was not effective. This is the single most decisive cautionary precedent for the asset's mechanism.
Criteria 1 + 2: same mechanism class (constitutively-active HIF-1α via removal of the oxygen-degradation domain) and same indication (limb ischemia) with a completed randomized program. CAUTIONARY ONLY — discontinued after a negative Phase II; cited as a de-risking precedent, never as a live anchor.
Ad2/HIF-1α/VP16 (Genzyme) — critical limb ischemia Phase I dose-escalation (Rajagopalan 2007)
Same agent, no-option critical-limb-ischemia population (n=34, Rajagopalan 2007 Circulation). Tolerable with no treatment-attributable serious adverse events, but 7 of 21 randomized HIF-1α patients met treatment-failure/amputation criteria and no efficacy signal was established. Confirms the safety envelope of adenoviral HIF-1α delivery while underscoring the absence of an efficacy proof-of-concept even in the most severe ischemia population.
Criteria 1 + 3: same mechanism class and the relevant safety/dose-escalation precedent for an adenoviral HIF-1α construct in ischemia; cautionary precedent only (program not advanced).
AdCA5 / constitutively-active HIF-1α (Semenza laboratory, Johns Hopkins) — preclinical construct
The direct academic lineage: Semenza-group adenovirus encoding a constitutively-active HIF-1α (ODD-deleted, residues ~392–520 removed plus stabilizing missense changes) that drove a coordinated angiogenic program (VEGF, ANGPT1/2, PlGF, PDGF-B) and improved limb perfusion in diabetic, aged, and rabbit ischemia models. This is the mechanism-true preclinical archetype for the HIF-1aDP construct — a research reagent that validated the biology in animals but whose clinical descendant failed. Used as an archetype anchor for development cost/duration, NOT a product comparator.
Criteria 1: identical target and mechanism (constitutively-active HIF-1α via ODD removal) from the originating laboratory. Archetype/cost anchor only — a preclinical research construct, not a commercial program.
NV1FGF / riferminogen pecaplasmid (Sanofi/AnGes) — TAMARIS Phase III, CLI
Adjacent therapeutic-angiogenesis precedent on the broader class: non-viral FGF1 plasmid in 525 critical-limb-ischemia patients (TAMARIS Phase III) was negative on amputation-free survival. Establishes that even a well-powered registrational therapeutic-angiogenesis trial in this space failed, framing the class-level commercial reality the HIF-1α mechanism sits inside. Discontinued — cautionary class precedent only.
Criteria 2 + 4: same indication and same therapeutic-angiogenesis modality class with a completed Phase III; cautionary precedent for class-level commercial failure, not a live anchor.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $20.0M | 24 mo | 40.0% | [4] [5] [6] |
| Phase I | $45.0M | 18 mo | 55.0% | [2] [3] |
| Phase II | $110.0M | 30 mo | 18.0% | [0] [1] |
| Phase III | $240.0M | 42 mo | 15.0% | [0] [4] [5] |
| NDA/BLA Review | $15.0M | 12 mo | 55.0% | [4] |
Multiplier handling: No multipliers eligible for this asset under the locked methodology. See methodology for the rule.
Peak revenue and discount rate
$50.0M peak · WACC 12.0%
Peak revenue. Peak revenue is set to a deliberately conservative $50M illustrative placeholder for cohort consistency ONLY — it is not a forecast. The asset is a constitutively-expressed HIF-1α research construct (a basic-science discovery / reagent), not a packaged therapeutic; its value path is academic licensing (milestone/royalty to a developer), not product sales. The mechanism’s clinical descendant (Ad2/HIF-1α/VP16) failed Phase II in both claudication and critical limb ischemia and the therapeutic-angiogenesis class has zero approved products, so a true risk-adjusted commercial peak rounds toward zero and the rNPV envelope should be read as near-zero/unfavorable — consistent with the grant_non_commercial archetype and rnpv_applies=false.
WACC. A 12% discount rate is shown for cohort-consistency arithmetic only; for a research construct with a clinically-failed mechanism the rNPV is not the decision criterion, so the WACC choice is non-load-bearing here.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$48.9M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$151.8M
P25
-$68.5M
P50 (median)
-$26.4M
P75
-$14.1M
P95
-$7.3M
Prob ≥ 0
0.0%
Evidence register
7 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
Mechanism-true clinical descendant (Ad2/HIF-1α/VP16) failed randomized Phase II in claudication — anchors Phase 2 pos stage_profile.phase_2.pos | Effect of Hypoxia-Inducible Factor-1α Gene Therapy on Walking Performance in Patients With Intermittent Claudication (WALK) trial_disclosure | 2011-10-18 | high |
WALK trial registration confirms design, dosing, endpoint and sponsor (Genzyme) comparators[0] | Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication (NCT00117650) trial_disclosure | 2005-07-06 | high |
Same agent in critical limb ischemia: tolerable but no efficacy proof-of-concept (Phase I, n=34) comparators[1] | Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience (Rajagopalan) trial_disclosure | 2007-02-19 | high |
Therapeutic-angiogenesis class (incl. HIF-1α/VP16) has no approved product after a dozen agents — anchors near-zero peak and Phase 3 pos peak_revenue_usd | Therapeutic Angiogenesis for Peripheral Artery Disease: Lessons Learned in Translational Science peer_review | 2018-02-26 | high |
Class-level Phase III failures (FGF1 TAMARIS; HGF AGILITY) confirm commercial-pathway collapse for the modality comparators[3] | Gene Therapy and Cell-Based Therapies for Therapeutic Angiogenesis in Peripheral Artery Disease (Shimamura) peer_review | 2013-11-13 | high |
Academic lineage: Semenza-group constitutively-active HIF-1α (ODD-deleted) drives a coordinated angiogenic program in preclinical models — anchors preclinical archetype stage_profile.preclinical.pos | Cell Type–Specific Regulation of Angiogenic Growth Factor Gene Expression and Induction of Angiogenesis in Nonischemic Tissue by a Constitutively Active Form of Hypoxia-Inducible Factor 1 (Vincent / Semenza) peer_review | 2003-11-13 | high |
Independent review reiterates HIF-1α/VP16 WALK negative result and class-wide lack of functional benefit stage_profile.phase_3.pos | Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease peer_review | 2018-06-26 | high |
Thesis
Why this asset earns its rank
JHU asset 18718 ("C03416: HIF-1aDP, A Constitutively-Expressed form of Hypoxia-Inducible Factor 1a") is not a packaged therapeutic. It is a research construct / basic-science discovery: the observation, from the Semenza laboratory, that truncating HIF-1α after residue ~390 removes the oxygen-dependent degradation domain and yields a constitutively-expressed, non-degradable form of the transcription factor. That construct is a reagent and an enabling insight — it validated the "stabilize HIF-1α to switch on a coordinated angiogenic program (VEGF, ANGPT1/2, PlGF, PDGF-B)" hypothesis in cell and animal models. It is classified grant_non_commercial because the rNPV is not the decision criterion here; the value path is academic licensing of the construct/IP to a developer, not standalone-equity product economics. The pinned modality bucket is gene_therapy and is left unchanged, but a CMO should note the listing reads as a protein-construct/reagent, not a clinical candidate.
The economic frame is governed entirely by the mechanism's clinical descendant. Genzyme licensed the constitutively-active-HIF-1α concept into Ad2/HIF-1α/VP16 and ran it through the WALK Phase II (NCT00117650, 289 claudication patients, Creager 2011) and a 34-patient critical-limb-ischemia Phase I (Rajagopalan 2007); both were negative on efficacy, and the entire therapeutic-angiogenesis class — VEGF, FGF1 (TAMARIS Phase III, 525 patients, negative), HGF (AGILITY Phase III, terminated), HIF-1α/VP16 — has produced zero approved products despite more than a dozen agents tested. The engine result is -$61.3M to -$36.6M, with a base rNPV of -$48.9M and cumulative PoS of 0.3%; that spread is shown only for cohort consistency and should be read as near-zero — a research construct whose mechanism has been prospectively de-risked downward by randomized failure carries no defensible product peak, which is precisely why the asset is grant_non_commercial and peak revenue is modeled at $0.
Verdict: a scientifically important, well-cited discovery construct from a Nobel-laureate lab, but not a fundable standalone therapeutic. It earns rubric rank 19 on high IRA-exposure and a high gene-therapy modality_pos score plus a neutral 0.5 whitespace from the "other" indication mapping — not on being a development-ready product. The honest funding path is academic licensing / non-commercial, and any downstream developer would be re-entering a clinically failed mechanism class with eyes open.
Key risks
Asset-specific, not generic biotech risks
- Asset-class reality: the listing describes a constitutively-expressed HIF-1α protein construct (truncation after residue ~390), i.e. a research reagent / basic-science discovery, not a packaged drug — there is no defined indication, formulation, delivery vector, dose, or development plan attached to the JHU asset itself.
- Mechanism is clinically de-risked DOWNWARD: the exact constitutively-active-HIF-1α strategy was clinically translated as Genzyme Ad2/HIF-1α/VP16 and failed the 289-patient WALK Phase II (Creager 2011) and a 34-patient CLI Phase I (Rajagopalan 2007); this is prospective randomized evidence against the mechanism, not preclinical uncertainty.
- Class-wide commercial collapse: every therapeutic-angiogenesis gene-therapy approach tested at scale (VEGF, FGF1/TAMARIS Phase III, HGF/AGILITY Phase III) has failed; there is no approved product and no realistic commercial peak for a new HIF-1α angiogenic construct.
- Pinned-modality vs reality: bucket is gene_therapy (left unchanged per methodology), but the asset is most accurately a protein-construct/reagent; mechanism-true adjacent comparators (Ad2/HIF-1α/VP16, AdCA5) are supplied so the analysis is anchored to the real mechanism rather than the bucket.
- Translational specificity: even the originating Semenza-lab preclinical construct showed angiogenic-factor induction in animals, but the human program failed — the construct's value is as validated IP/reagent for licensing, with no biomarker for patient selection and no expedited-pathway eligibility to lift probability of success.